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Abstract: DDX6 (p54/RCK) is a human RNA helicase with central roles in mRNA decay 
and translation repression. To help our understanding of how DDX6 performs these 
multiple functions, we conducted the first unbiased, large-scale study to map the DDX6-centric 
protein-protein interactome using immunoprecipitation and mass spectrometry. Using DDX6 
as bait, we identify a high-confidence and high-quality set of protein interaction partners 
which are enriched for functions in RNA metabolism and ribosomal proteins. The screen is 
highly specific, maximizing the number of true positives, as demonstrated by the validation 
of 81% (47/58) of the RNA-independent interactors through known functions and interactions. 
Importantly, we minimize the number of indirect interaction partners through use of a 
nuclease-based digestion to eliminate RNA. We describe eleven new interactors, including 
proteins involved in splicing which is an as-yet unknown role for DDX6. We validated 
and characterized in more detail the interaction of DDX6 with Nuclear fragile X mental 
retardation-interacting protein 2 (NUFIP2) and with two previously uncharacterized 
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proteins, FAM195A and FAM195B (here referred to as granulin-1 and granulin-2, or GRAN1 
and GRAN2). We show that NUFIP2, GRAN1, and GRAN2 are not P-body components, 
but re-localize to stress granules upon exposure to stress, suggesting a function in translation 
repression in the cellular stress response. Using a complementary analysis that resolved 
DDX6’s multiple complex memberships, we further validated these interaction partners 
and the presence of splicing factors. As DDX6 also interacts with the E3 SUMO ligase 
TIF1, we tested for and observed a significant enrichment of sumoylation amongst 
DDX6’s interaction partners. Our results represent the most comprehensive screen for 
direct interaction partners of a key regulator of RNA life cycle and localization, highlighting 
new stress granule components and possible DDX6 functions—many of which are likely 
conserved across eukaryotes. 
Keywords: DDX6; post-transcriptional regulation; protein interactions; SUMOylation; 
NUFIP2; FAM195A; FAM195B; stress granules; P bodies; mRNA degradation 
 
1. Introduction 
The concentrations of cellular proteins are finely tuned by a wide variety of regulatory mechanisms 
at the level of transcription, translation, and degradation. While transcription regulation is an essential 
process, some studies indicate that post-transcriptional regulation also plays a large role [1–4], 
encompassing for example RNA processing, storage, degradation, and translation. Over a thousand 
human proteins appear to have RNA binding functions and therefore putative roles in post-transcriptional 
regulation [5]. However, in-depth knowledge of the molecular functions, targets, and binding sites is 
still limited to only several dozen RNA-binding proteins (RBPs) [5–7]—and an accurate understanding 
of the regulation of protein expression requires further exploration of the network of post-transcriptional 
regulators with respect to their localization, interaction partners, and functions. 
The mammalian DEAD-box RNA helicase DDX6 (also known as p54/Rck) impacts protein 
expression in several ways [8–11]. Current research suggests that DDX6 may be involved in several 
key functions of RNA metabolism, determining determine whether an mRNA is destined for 
translation, storage, or decay [12–16]. Mechanistic effects of the yeast DDX6 ortholog, Dhh1p,  
on gene expression have been well studied, with translation being repressed at the initiation phase in a 
nutrient-responsive manner [16]. Dhh1p also associates with ribosomes, and inhibits mRNA 
translation concomitant with the elongation step when tethered to the mRNA [17]. With respect to 
mRNA decapping, DDX6 is important for assembly of the decapping complex [18], and may 
stimulate DCP2 activity [15]. DDX6-dependent inhibition of protein synthesis (i.e., translation 
inhibition and mRNA decapping) is thought to converge in the miRNA-silencing pathway, where 
efficient miRISC-dependent repression requires DDX6 [19]. Thus, while DDX6 is required for 
miRNA silencing, the precise manner by which DDX6 is recruited to miRNA targets remains poorly 
understood [20]. DDX6 has also been linked to human disease both as a proto-oncogene in several 
types of cancer [21–24], and as a facilitator of the infection process by a number of viruses including 
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HIV and the hepatitis C virus [25–28]. However, the exact mechanisms by which DDX6 contributes  
to these pathogenic processes are yet to be determined. 
Both the sequence and functions of DDX6 are conserved in a variety of organisms including  
S. cerevisiae (DHH1) [29], S. pombe (STE13) [30], C. elegans (CGH-1) [31], D. melanogaster 
(Me31B) [32], X. laevis (XP54) [33], and mammals [34]. DDX6 has a complex localization pattern:  
it stains diffusely in the nucleus and cytoplasm, and localizes both constitutively and during stress to at 
least two different mRNA-protein (mRNP) structures in the cytoplasm, i.e., stress granules and  
P-bodies [35–38]. The multiple niches to which DDX6 localizes likely reflect the multiple molecular 
mechanisms by which DDX6 influences post-transcriptional gene regulation [39]. In one of these 
functions, DDX6 enhances mRNA decay via the decapping pathway, a role which has been associated 
with cytoplasmic structures known as P-bodies or GW bodies [14,35,40]. DDX6 is also involved in the 
repression of mRNA translation at a step following initiation [16,17,41,42]. Under cellular stress, this 
translation repressor function has been linked to the storage of mRNAs in cytoplasmic bodies known 
as stress granules [37]. P-bodies, which are constitutively present in most cell types, have an 
overlapping but distinct protein composition as compared with stress granules, which are inducibly 
assembled when global protein synthesis is inhibited in response to stress [43]. Finally, DDX6 can 
alter protein levels via regulation of microRNA activity [8,9,20,44,45]. 
Despite much recent investigation [11,13,20,46,47], the mechanisms by which DDX6 carries out 
these diverse functions are still not well understood. A small number of interactions between DDX6 
and other proteins have been characterized in several organisms, but overall the evidence is fragmented 
and anecdotal. For example, DDX6 is known to interact with the decapping proteins DCP1 and EDC3 
in processing bodies (P bodies), forming a complex which mediates de-adenylation dependent mRNA 
decay [14,35,40,48]. An interaction between DDX6 and the Argonaute proteins, which work in  
concert with miRNAs to regulate protein levels, has also been posited to occur within P-bodies [44]. 
DDX6 has further been shown to interact with the translation repressors ataxin-2/ataxin-2 like protein 
(ATXN2/ATXN2L) and polyadenylate-binding protein 1 (PABPC1) both under normal conditions 
(where no stress granules are present), and within stress granules under appropriate conditions [37,49]. 
While these known DDX6 interactions are suggestive of the mechanisms by which DDX6 exerts its 
influence on post-transcriptional regulation, only a systematic and comprehensive investigation of  
the protein interaction partners enables us to fully understand the scope and mechanism of DDX6 
function. We undertook such an unbiased study of the DDX6-centric protein interactome to shed light 
on its role in post-transcriptional regulation of cellular protein levels. As a result, we have expanded 
our knowledge of the proteins involved in DDX6-mediated processes, and identified, verified, and 
characterized new proteins which re-localize to stress granules under conditions of cellular stress. 
2. Results 
2.1. Identification of DDX6-Interacting Proteins 
To identify proteins which interact with DDX6, we created an HEK293-based cell line which stably 
expresses DDX6 fused with an N-terminal FLAG/HA-tag under control of a tetracycline-inducible 
promoter (293-DDX6-FH). Previous reports indicate that high-level overexpression of DDX6 can 
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induce the formation of additional P bodies, as observed for other P body proteins [16,50]. To avoid 
this scenario, we selected a clone of the 293-DDX6-FH line which upon induction resulted in expression  
of DDX6-FLAG-HA at approximately 80% of the level of wild type DDX6 expression (Figure 1A). 
Repeat experiments demonstrated that this clone reproducibly results in FLAG/HA-DDX6 levels of  
70%–90% of endogenous DDX6 levels after 18 h of doxycycline induction. We further confirmed that 
the DDX6-FLAG-HA protein localizes to P bodies in a manner indistinguishable from that of 
endogenous DDX6 (Figure 1B), and that the average number of P bodies per cell is unchanged by 
DDX6-FLAG-HA expression (Figure 1C). These results suggest that the DDX6 transgene is fully 
functional in terms of localization, and does not alter cellular mRNP composition. 
 
Figure 1. Validation of double-tagged DDX6 construct to ensure highly specific interaction 
screen. (A) Exogenously expressed DDX6 has physiological expression levels. Western  
blot analysis of whole cell lysates from HEK-293 cells (lane 1) or HEK-293 cells containing  
the DDX6-FLAG-HA construct under control of a tetracycline-inducible promoter  
(lanes 2 and 3). DDX6-FH = FLAG-HA-tagged DDX6 construct inducibly expressed from  
293-DDX6-FH cells. End-DDX6 = endogenous DDX6; (B) Exogenously expressed 
DDX6 localizes to the expected cellular compartments. Immunofluorescence analysis 
of HEK-293-DDX6-FLAG-HA cells, in the absence or presence of doxycycline, with 
antibodies against endogenous DDX6 or the HA epitope tag; (C) Quantification of the 
average number of P bodies per cell in HEK-293 cells as compared to 293-DDX6-FH cells 
in the absence or presence of doxycycline. 
We employed two major approaches to characterize both the direct and indirect interaction partners 
for DDX6 (Figure 2A). First, we used the double-tagged DDX6 protein as bait in a tandem-pulldown 
experiment which, due to the two consecutive purification steps is likely to be enriched in true-positive 
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interaction partners. To do so, we harvested whole cell lysate from 293-FLAG-HA cells treated with 
doxycycline, and performed a tandem immunoprecipitation (IP) against the FLAG and HA epitope 
tags. RNA-dependent interactions, i.e., proteins bound to the same RNA but not to DDX6, were 
removed by benzoase treatment, a highly active nuclease which nonspecifically degrades both  
RNA and DNA. Identical experiments performed in doxycycline-treated HEK293 cells lacking the  
DDX6-FLAG-HA construct served as a control for non-specific binding. The purified proteins were 
digested with trypsin and the resulting peptides were identified by mass spectrometry. Second, in a 
complementary approach, we used single-pulldown of DDX6 and native-gel electrophoresis to 
separate different protein complexes involving DDX6. Importantly, our protocol involves a benzoase 
digestion step which removes all RNA. Therefore, in contrast to many other studies, e.g., [51], our 
results report very few false-positive interaction partners, i.e., proteins that are purely reported due to 
their binding to the same RNA. 
 
 
Figure 2. DDX6-interacting proteins belong to three major categories. (A) Graphical 
representation of interaction types identified in this screen. Blue—direct interactions, 
enriched in pulldown of double-tagged DDX6. Red—complex interactions, identified in 
native gel experiment. Grey—RNA-dependent interactions; (B) DDX6-interacting proteins 
identified in this screen. The novel, non-ribosomal proteins, likely to be direct interaction 
partners, are emphasized in blue. Each pie wedge is labeled with the number of proteins 
identified in that category. 
Several criteria were applied to ensure the validity of the list of DDX6-interacting proteins. We 
applied a 5% false discovery rate cutoff to each individual replicate, and included only proteins which 
were identified by at least one peptide in a minimum of two biological replicates of one experimental 
condition (control HEK293 vs. experimental 293-DDX6-FH IP) on the list. Furthermore, any protein 
identified by a single peptide in the control IP was considered a contaminant and excluded from the 
list, as were all keratins, histones, and immunoglobins. These strict criteria ensure high confidence in 
the identified proteins. 
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Applying these criteria, a total of 81 proteins were identified in the tandem-pulldown 
experiment, including DDX6 itself (Supplementary data). We subdivided the list into several 
categories (Figure 2B). As could be expected, we identified more RNA-dependent than independent 
interactions (Supplementary data). The 23 RNA-dependent proteins are enriched in RNA-binding 
functions (GO: 0003723), and likely identified due to binding of a common RNA molecule, without 
maintaining a direct protein-protein interaction. In agreement with this interpretation, none of the 
RNA-dependent DDX6 interactors had previously been identified as directly binding to DDX6. 
A second group of proteins identified as interacting with DDX6 is composed of ribosomal 
proteins from both the large and small ribosomal subunits (Supplementary data and Figure 2B).  
A physical interaction between DDX6 and the ribosome is not surprising, given the previously 
documented interaction of the yeast ortholog DHH1 with the ribosome [17], and the documented 
role of DDX6 in the regulation of translation efficiency [16,17]. In the interest of focusing on 
previously uncharacterized DDX6 protein partners, interactions with the ribosome will not be 
further discussed here. 
We identified 29 non-ribosomal proteins as interacting with DDX6, independent of RNA presence, 
and these proteins represent a core which we examined in more detail (Table 1 and Figure 2B). 
Amongst the proteins, several functional categories were significantly enriched: RNA binding  
(p = 4.7 × 108), deadenylation-dependent mRNA decay and P-bodies (p = 2.2 × 107), and 
cytoplasmic stress granules (p = 3.2 × 107). These categories are in accordance with the known 
functions of DDX6 in mRNA decay, and its localization to cytoplasmic stress granules [52]. There 
is a high degree of interconnectivity within the DDX6 interactome, as 25 of the 29 DDX6-interacting 
proteins identified in this study have been shown to bind at least one other protein within this 
group (Supplementary data). 
A literature search reveals that 18 of the proteins have previously been shown to interact with 
DDX6: the ATXN2/ATXN2L-PABPC1 complex, the DCP1-EDC3-PAT1L decapping complex, 
LSM14A, transcription intermediary factor 1-beta (TIF1B), and eukaryotic translation initiation 
factor 4E transporter (EIF4ENIF1), FAM195A and FAM195B [37,40,48,49,52–54]. For several other 
proteins, i.e., LSM14B, EDC3, NUFIP2, other large-scale screens reported possible complex or indirect 
interactions (Table 1). Other proteins are known to be components of stress granules, P-bodies, or 
the decapping complex which are all functions that are known to involve DDX6 (Table 1). These 
known interactions and functions to verify that our interaction screen is highly specific. 
In total, eleven (19%) of the identified proteins represent novel interactions with DDX6 in the 
context of human cells that have the potential to provide insight into DDX6-mediated cellular 
processes (Table 1). Six of these new interactors, namely C1QBP, DDX17, HNRNPC, HNRNPM, 
RTCB, and THRAP3, are annotated as splicing factors—a function that DDX6 has not previously  
been implicated in. 
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Table 1. Interaction partners, independent of binding to RNA. 
Gene Name Protein Name SG TL PB DC Status SF 
ATXN2 ataxin 2 X X X  BG X 
ATXN2L ataxin 2-like X  X  BG X 
C1QBP 
complement component 1,  
q subcomponent binding protein 
    New X 
DCP1B DCP1 decapping enzyme homolog B   X X BG  
DDX1 DEAD (Asp-Glu-Ala-Asp) box helicase 1 X X   Inf X 
DDX17 DEAD (Asp-Glu-Ala-Asp) box helicase 17     New X 
EDC3 enhancer of mRNA decapping 3 homolog   X X BG  
EDC4 enhancer of mRNA decapping 4   X X BG  
EIF4ENIF1 
eukaryotic translation initiation factor 4E  
nuclear import factor 1 
    BG  
ERH enhancer of rudimentary homolog (Drosophila)     New  
FMR1 fragile X mental retardation 1 X X   New  
FXR2 fragile X mental retardation, autosomal homolog 2  X   New  
G3BP2 
GTPase activating protein (SH3 domain) binding 
protein 2 
X    BG  
GRAN1/ 
FAM195A 
family with sequence similarity 195, member A X***    BG  
GRAN2/ 
FAM195B 
family with sequence similarity 195, member B X***    BG  
HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2)     New X 
HNRNPM heterogeneous nuclear ribonucleoprotein M     New X 
LARP4 La ribonucleoprotein domain family, member 4     New  
LSM12 LSM12 homolog     BG  
LSM14A LSM14A, SCD6 homolog A X X X  BG  
LSM14B LSM14B, SCD6 homolog B  X   BG X 
NUFIP2 
nuclear fragile X mental retardation protein  
interacting protein 2 
X***    BG  
PABPC1 poly(A) binding protein, cytoplasmic 1 X X   Inf X 
PABPC3 poly(A) binding protein, cytoplasmic 3 X    Inf  
PABPC4 poly(A) binding protein, cytoplasmic 4 (inducible form) X X   Inf X 
PATL1 protein associated with topoisomerase II homolog 1   X X BG  
RTCB RNA 2',3'-cyclic phosphate and 5'-OH ligase     New X 
THRAP3 thyroid hormone receptor associated protein 3     New X 
TIF1B tripartite motif containing 28     New  
Proteins identified by mass spectrometry from samples generated by immunoprecipitation of DDX6 from nuclease-treated 
samples. Status—status of interaction (New—interaction partner newly detected in this screen; Inf—interaction can be 
inferred from DDX6’s new function in DC, SG, TL, or PB; BG—interaction with DDX6 reported in Biogrid [55]).  
SG—stress granules. TL—translation. PB—processing bodies. DC—decapping complex. SF—splicing factor. ***—as 
demonstrated in this paper. 
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2.2. Validation and Characterization of Direct Interactions with NUFIP2, GRAN1 (FAM195A), and 
GRAN2 (FAM195B) 
We chose three of the DDX6-interacting proteins for further validation and characterization as very 
little or nothing was known about their function: NUFIP2, FAM195A, and FAM195B. FAM195A and 
FAM195B have recently been listed as DDX6 interaction partners in a large-scale experiment [53],  
but this result has not yet been validated or characterized. Due to results that will be discussed below, 
we have renamed the genes as granulin-1 (GRAN1, FAM195A) and granulin-2 (GRAN2, FAM195B). 
NUFIP2 has also not been well-characterized, but has been shown to associate with Fragile X  
Mental Retardation Protein (FMR1, also identified as DDX6-interacting protein in this study) and the 
polysome [56,57]. First, to confirm the interactions with DDX6, we performed an immunoprecipitation 
using anti-FLAG antibodies in lysate prepared from 293-DDX6-FH cells, and subjected the purified 
proteins to Western blot with antibodies specific to NUFIP2, GRAN1, and GRAN2 (Figure 3A). For 
all three antibodies, a band was identified at the correct molecular weight in whole cell lysates. A 
similar band was observed when blotting proteins purified specifically in the IPs from 293-DDX6-FH 
cells but not the control HEK-293 cells, validating the interactions observed by mass spectrometry. 
We then examined the co-localization of NUFIP2, GRAN1, and GRAN2 with DDX6 by 
performing immunofluorescence experiments in HEK-293 cells with antibodies specific to each 
protein. All three proteins showed dual localization to the cytoplasm and nucleus, and they exhibit 
diffuse staining both in the nucleus and cytoplasm which overlap with the diffuse DDX6 staining 
(Figure 3B). However, none of the three proteins stain within P bodies, as can be seen by the lack of 
co-localization in the DDX6-positive cytoplasmic foci (Figure 3B). 
GRAN1 and GRAN2 are small proteins distinguished primarily by the presence of the FAM195 
protein domain (Figure 4A). They have not yet been described in literature. Mass spectrometry data 
indicates that both GRAN1 and GRAN2 possess a similar cluster of phosphorylation sites in the  
N-terminal side of the FAM195 domain (Figure 4A) [58]. GRAN1 and GRAN2 protein levels appear 
to be influenced by DDX6 expression, as induction of DDX6 overexpression in 293-DDX6-FH cells 
by doxycycline treatment induced a significant increase in GRAN1 and GRAN2 levels compared to 
the loading control of beta-actin, as measured by Western blotting of whole cell lysates (Figure 4B). 
This increase in GRAN1 and GRAN2 expression could happen through a number of different 
mechanisms, including translational regulation or stabilization of GRAN1 and GRAN2 protein levels 
via complex formation with DDX6. 
Next, because of their similar localization patterns, we tested whether GRAN1 and GRAN2 interact 
by immunoprecipitating GRAN2 from HEK293 cells and blotting for GRAN1 and DDX6 (Figure 4C). 
This experiment indicates that GRAN1 and GRAN2 do interact, and also confirms the DDX6 
interaction via a reciprocal co-immunoprecipitation. 
We next examined the subcellular localization pattern of GRAN1, GRAN2, and NUFIP2, to gain 
additional insight into their potential functions. DDX6 undergoes a change in subcellular localization 
after exposure of cells to various types of stress that induce the formation of stress granules [37,38]. 
DDX6 can still be found in P bodies under these conditions, but some fraction of DDX6 protein also  
re-localizes to stress granules. We hypothesized that, since NUFIP2, GRAN1, and GRAN2 are not 
found in P bodies, they might instead localize to stress granules under the appropriate conditions. This 
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hypothesis is strengthened by the observation that both NUFIP2 and GRAN1 contain Q/N-rich regions 
(Figure 4A) which have been shown in other proteins to mediate localization to cytoplasmic mRNP 
particles such as stress granules [59]. Furthermore, NUFIP2 precipitates from cells after treatment with 
biotinylated 5-aryl-isoxazole-3-carboxyamide, a compound which induces the precipitation of many 
RNA binding proteins which are constituents of mRNP granules [60]. 
To test the hypothesis that GRAN1, GRAN2, and NUFIP2 might localize to other mRNP granules, 
we treated HEK293 cells with arsenite, a reagent known to induce stress granules. We then performed 
double-immunofluorescence imaging to co-localize these proteins with PABPC1, a well-characterized 
marker of stress granules (Figure 4D). GRAN1, GRAN2, and NUFIP2 all exhibited a dramatic change 
in sub-cellular localization upon arsenite treatment, forming cytoplasmic foci that perfectly overlap 
with stress granules (Figure 4D). These data, combined with their interaction with DDX6, suggests a 
role for these three proteins in granule formation after stress. 
 
Figure 3. Validation of direct interactions—characterization of new genes. (A) DDX6 interacts 
with NUFIP2, GRAN1, and GRAN2. Whole cell lysate (lanes 1 and 2) or tandem FLAG/HA 
immunoprecipitates (lanes 3 and 4) were probed by Western blot with antibodies against 
the HA epitope tag, NUFIP2, GRAN1, GRAN2 or beta-actin (loading control). The 
experiment was performed in HEK-293 cells (control) or in 293-DDX6-FH cells induced 
with doxycycline as indicated; (B) NUFIP2, GRAN1, and GRAN2 do not localize to P 
bodies. For the co-localization of DDX6 with GRAN1, GRAN2, and NUFIP2, cells were 
double-stained with an antibody against DDX6 (red) and the interacting proteins as 
indicated (green). Nuclei are marked with DAPI. White arrows indicate the location of a 
DDX6-positive P body. 
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Figure 4. GRAN1, GRAN2, and NUFIP2 localize to stress granules upon arsenite 
treatment. (A) Domain structure and features of GRAN1 (FAM195A) and GRAN2 
(FAM195B). Green = FAM195 domain [61]. PRR = proline-rich region. NES = nuclear 
export signal [62,63]. Purple stars = serine/threonine phosphorylation sites from the 
PhosphoSite database [58]; (B) GRAN1 and GRAN2 protein levels increase upon induction 
of DDX6 overexpression. Whole cell lysates from 293-DDX6-FH in the absence or 
presence of doxycycline were separated by SDS-PAGE and blotted with the indicated 
antibodies; (C) GRAN1 and GRAN2 form a physical complex. An immunoprecipitation 
experiment with an anti-GRAN2 antibody was subject Western blot with antibodies 
that recognize GRAN2 and DDX6; (D) NUFIP2, GRAN1, and GRAN2 localize to 
stress granules. HEK293 cells were either mock-treated (-) or subject to arsenite (ars) 
treatment (50 mM, 1 h) prior to immunofluorescence staining with antibodies against 
NUFIP2, GRAN1, or GRAN2. Stress granules were identified by staining with the 
stress granule marker PAPB, and DAPI marks the location of the nucleus. White arrows 
indicate stress granules. 
Biomolecules 2015, 5 1451 
 
 
2.3. Further Functional Characterization of the DDX6 Interactome 
Based on the data discussed above (Table 1) and literature evidence, we hypothesized that 
DDX6 belongs to several distinct multi-protein complexes, playing a role in different aspects of 
RNA metabolism (e.g., decapping, splicing, translation regulation, transport), is localized to different 
cellular compartments (e.g., P bodies, stress granules, diffuse cytoplasmic and nuclear staining). 
To test this hypothesis, we purified DDX6-protein complexes by immunoprecipitation from  
293-DDX6-FH cells, and separated the intact protein complexes by blue native polyacrylamide gel 
electrophoresis [64–66]. The gel lanes from control (HEK293) or 293-DDX6-FH samples were cut 
into thirty 2 mm slices, and the protein contents were analyzed by mass spectrometry. Identified 
proteins were classified as either P-body, stress granule, or splicing factors (Figure 5A,B). 
We then plotted the number of unique peptides identified in each group according to the gel 
region which roughly corresponds to the molecular weight of the intact protein complex. Proteins 
with ambiguous group membership were excluded. In this graph, we note a single peak of splicing 
factors in the lower molecular weight region (corresponding to approximately 150–300 kD), 
accompanied by elution of the ribosomal proteins (Figure 5A,B). Notably, elution of splicing 
proteins is dominated by C1QBP, a protein involved in regulation of RNA splicing by inhibiting 
the RNA-binding capacity of SRSF1 and its phosphorylation [67]. Is required for the nuclear 
translocation of splicing factor U2AF1L4 [67]. An interaction with DDX6 has not yet been described. 
In the middle molecular weight regions, only the P body proteins are present. In addition,  
at high molecular weights, both P body and stress granule proteins form an overlapping peak  
(Figure 5A,B). The co-elution of P-body and stress granule components illustrates the overlapping 
functionalities and protein membership of these protein complexes. The elution of NUFIP2, 
GRAN1, and GRAN2 with other known members of stress granules confirms our findings from 
above on these proteins being new stress granule components (Figure 5B). The separation of 
protein complexes by molecular weight according to function suggests that DDX6 likely functions 
in a number of different protein complexes with different functions. 
One of the novel DDX6-interacting proteins, TIF1 (Table 1), has recently been identified as  
an E3 ligase for the small ubiquitin-like protein SUMO [68,69]. Indeed, in one high-throughput 
study that used mass spectrometry to identify SUMO-conjugated proteins, DDX6 is identified as a 
sumoylation substrate [70]. We therefore set out to confirm whether DDX6 is sumoylated. We 
purified DDX6 from 293-DDX6-FH cells by immunoprecipitation, and blotted with an antibody 
against SUMO1. We observed a band at approximately 65 kD (Figure 5C), leading to the 
conclusion that DDX6 is sumoylated. 
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Figure 5. Functional characterization of the DDX6 interactome—complex interactions and 
SUMOylation. (A) Analysis of DDX6-protein complexes by native gel electrophoresis 
shows that the different functional groupings of DDX6-interacting proteins migrate at different 
rates, indicating the possibility of distinct DDX6 complexes with different cellular functions. 
Gel regions represent the combined results from three adjacent gel slices. Proteins with known 
exclusive membership to a functional class localization (SF—Splicing Factor, PB—Processing 
bodies, SG—Stress Granules) were grouped and unique peptide counts totaled for the group; 
(B) Distribution of proteins across slices from native gel electrophoresis. We report the 
number of peptides found for each protein in each slice and their localization. Functional 
categories as in (A). Highlighted in blue are NUFIP2, GRAN1, and GRAN2 which are 
further validated and characterized here. The complete dataset is shown in the Supplementary 
data; (C) DDX6 was immunoprecipitated from HEK293 or 293-DDX6-FH cells via a tandem 
FLAG-HA immunoprecipitation, separated by SDS-PAGE, and blotted with antibodies against 
SUMO1 and the HA tag to identify sumoylated forms of DDX6; (D) DDX6-interacting 
proteins are significantly enriched in the number of sumoylation sites per protein (t-test,  
p = 4.1 × 105). 
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We then hypothesized that other members of the DDX6 interactome might be similarly sumoylated. 
A recent study lead by Mann’s group and many other studies that use proteomic approaches to identify 
sumoylated proteins independently concluded that the identified SUMO-conjugated proteins are highly 
enriched for proteins involved in RNA metabolism and RNA binding [70–79]. To test whether  
DDX6-interacting proteins are enriched for sumoylation, we compiled a database of human  
proteins which have been identified as sumoylated from 14 high-throughput mass spectrometry  
studies [70–74,77,80–87] (Supplementary data). We included a diverse array of studies, including 
purifications of SUMO1, SUMO2, and SUMO3, as well as varied purification techniques and 
experiments performed under stress conditions such as heat shock or oxidative stress, to obtain as wide 
a representation of the sumoylated universe as possible. In total, 1892 proteins from these studies could 
be mapped to unique gene identifiers. Of these proteins, 853 were identified by at least two 
independent studies, and therefore should be considered a core set with especially strong evidence of 
sumoylation. Of the 29 proteins that we identified as interacting with DDX6 (Table 1), 13 were found 
to be members of this core set of sumoylated proteins, representing a highly significant enrichment in 
comparison to the human proteome (hypergeometric test, p = 3.4 × 1011) (Figure 5C). This enrichment 
remains significant even when considering the set of all proteins detected in sumoylation studies 
instead of the entire proteome (19 of 29, p = 5.6 × 109). In fact, one of the interactors, heterogeneous 
nuclear ribonucleoprotein M (HNRNPM), is one of the two most frequently-identified sumoylated 
proteins known, occurring as a hit in ten of the 14 studies examined (Supplementary data). Conversely, 
analysis of the human proteome with SUMOsp software to identify high confidence sumoylation sites 
(both -K-x-E motif and non-consensus sites) found that the DDX6-interacting proteins identified in this 
paper contain significantly more sites than would be expected given their frequency in the proteome as  
a whole (Figure 5D, p = 4.1 × 105). 
3. Discussion 
An extensive body of literature documents the participation of DDX6 in a number of cellular 
processes, all of which contribute to post-transcriptional regulation and many of which are conserved 
throughout evolution [16,88,89]. However, the mechanisms by which a protein can act as a regulator 
are mostly based on interactions with other molecules. To help our understanding of the complex 
regulatory roles of DDX6, we have undertaken the first comprehensive DDX6-centric interaction 
screen, and characterized the protein interaction partners in a large-scale, comprehensive manner. To 
accurately and sensitively identify these proteins, we chose a tandem affinity purification strategy of 
DDX6 as the bait, coupled to high-resolution mass spectrometry. By combining different approaches, 
we distinguished functionally relevant interactions with DDX6 from interactions which depend on the 
mutual binding of RNA, and protein complex membership. 
DDX6 is often thought of as a marker of P-bodies [90], and the most well-characterized function of 
both DDX6 and its yeast ortholog DHH1 is in the mRNA decapping/decay pathway [14,47,88,89,91]. 
Consistent with this view, we identified a number of P-body/decapping proteins as DDX6 interactors 
(Table 1). Many of these interactions had previously been observed either in human or yeast in 
individual studies emphasizing the conservation of DDX6’s role across organisms [20,37,46,49,62]. We 
also identified a number of known and novel interacting proteins which localize to stress granules. Because 
Biomolecules 2015, 5 1454 
 
 
these experiments were performed under non-stressed conditions in which stress granules are not visible by 
microscopy, we conclude that DDX6 maintains stable interactions with stress granule proteins even in the 
absence of visible mRNP structures. Overall, the sheer number of P-body and stress granule proteins with 
which DDX6 interacts, in addition to the known mRNP remodeling function of DDX6, suggests that 
DDX6 may be a key factor in modulating the contents of P bodies and stress granules. Indeed, a recent 
publication [92] demonstrates a key role of DDX6 in P-body assembly. 
Notably, we did not identify any peptides from Argonaute proteins, even below the threshold for 
inclusion in our lists, despite evidence in the literature that such an Ago-DDX6 interaction does  
occur [44]. This finding is likely due to either the interaction being transient and not stable enough to 
persist during the tandem immunoprecipitation protocol, or the interaction taking place under conditions 
not tested here, or the interaction occurring at a level undetectable by mass spectrometry in the 
quantities used for our experiment. As we placed our screen’s emphasis on minimal false-positives,  
i.e., low number of falsely reported interaction partners, rather than minimal a few false-negatives,  
i.e., identification of all known partners, absence of the Argonaute proteins does not diminish the 
quality of our results. A list of proteins reported to interact with DDX6, but not observed in this study,  
is provided in the Supplementary Material. 
Recent studies identified a physical protein interaction network associated with miRNA biogenesis 
and regulation, using a proteomic approach [46,53]. The authors listed DDX6-interacting proteins, 
including NUFIP2, FAM195A and FAM195B, but without further validation. As very little is known 
about the three proteins, we confirm the interaction and we characterized the function of these proteins 
with respect to RNA-protein complex interactions. GRAN1 and GRAN2 bind DDX6 and are localized 
to the cytoplasm under normal conditions. Upon stress, GRAN1 and GRAN2 re-localize to stress 
granules, suggesting a potential role in translation repression in response to stress and presenting new 
stress granule components. This dynamic localization to stress granules may be facilitated by the  
Q/N-rich region in GRAN1. Due to their aggregation-prone nature, Q/N rich regions can be sufficient 
for localization of a variety of human proteins to P bodies [59,60]. As stress granule proteins also tend 
to have Q/N rich regions (e.g., ATXN2), the sequence may serve a re-localization function as well. 
Because GRAN1 and GRAN2 also interact with each other, GRAN2 could be recruited to stress 
granules via its interaction with GRAN1. In contrast to other interaction partners also reported in  
yeast, GRAN1 and GRAN2 have orthologs in other vertebrates, but not invertebrates or unicellular  
eukaryotes—suggesting that their role with DDX6 evolved only recently. 
The stress granule protein NUFIP2 is another novel DDX6 interaction partner which we 
characterized further. NUFIP2 was originally identified through its interaction with the Fragile X 
mental retardation protein FMR1, but nothing else is known about the protein. Interestingly, FMR1 
and its homolog FXR2 were also identified as interacting with DDX6 in this screen, suggesting a role 
of FMR1/FXR2 in stress that has not been described before. However, given the low relative 
quantification of each of these proteins in our experiments, the interaction between DDX6 and 
FMR1/FXR2 may be transient or indirect and mediated by the much more abundant NUFIP2. Both 
DDX6 and the FMR proteins are noted for their roles in translation repression, and in Drosophila, 
these proteins have been found to co-localize in neuronal granules, suggesting that they can work in 
the same pathway [93]. The common interaction with NUFIP2 suggests that further study of this 
protein may shed light on the nature of translation repression in stress granules. As a side note, 
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NUFIP2 also contains a Q/N rich region (as well as a proline-rich region), which might explain its 
localization to stress granules. 
Studies of protein-protein interactions can often identify potential new functions for a protein 
through analysis of the known functions of its interaction partners. Table 1 and Figure 5A,B show 
several proteins which function in RNA splicing. DDX6 has not previously been associated with 
splicing, and these data suggest a novel role for DDX6 that may explain its presence in the nucleus. 
Supporting this hypothesis, several mass spectrometry studies in yeast and human have identified 
DDX6 as a potential component of the spliceosome [94–96]. This observation could be explained by 
the fact that many nuclear mRNP that co-localize in P-bodies and stress granules during stress include 
factors involved in transcription, 3' end processing, splicing and export, which might affect also 
nuclear events [97]. 
Finally, we also detected an interaction between DDX6 and the E3 SUMO ligase TIF1.  
All evidence established to date says that TIF1 is an exclusively nuclear protein [98]. However, while 
DDX6 is primarily cytoplasmic, there is evidence that it shuttles between the nucleus and cytoplasm, 
creating an opportunity for sumoylation by TIF1 [99]. We confirmed that DDX6 is indeed 
sumoylated (Figure 5C) [70], and also demonstrate significant SUMOylation for the DDX6 interactome 
(Figure 5D). One intriguing hypothesis for the mechanism of SUMOylation amongst these RNA-binding 
proteins is based on the fact that SUMO is one of the most soluble of all known proteins [100], and it 
may be involved in preventing aggregation within densely packed cellular structures such as  
these granules [101]. As many or most of the DDX6-interacting proteins localize to P bodies and/or  
stress granules, and this localization is known to depend on a variety of aggregation-prone domains,  
we hypothesize that maintenance of a certain level of sumoylation of these proteins prevents  
uncontrolled aggregation during the assembly of cytoplasmic mRNP granules. Uncontrolled mRNP  
assembly via these low complexity domains has been posited to contribute to a variety of  
neurodegenerative disorders [102]. 
4. Experimental Section 
4.1. Generation of Cell Lines 
pENTR constructs were generated by PCR amplification of the respective coding sequences 
(CDS) from Flp-In 293 T-REx derived cDNA, followed by restriction digest and ligation into 
pENTR4 backbone (Invitrogen, Carlsbad, CA, USA). pENTR vectors carrying CDS were recombined 
into pFRT/TO/FLAG/HA-DEST destination vector using GATEWAY LR recombinase according to 
manufacturer’s protocol (Life Technologies, Carlsbad, CA, USA). Cell lines stably expressing 
FLAG/HA-tagged DDX6 protein were generated by co-transfection of pFRT/TO/FLAG/HA 
constructs with pOG44 into Flp-In 293 T-REx cells (Life Technologies). Cells were selected by 
exchanging zeocin for 100 μg/mL hygromycin, and monoclonal colonies were isolated. 
4.2. Cell Culture 
HEK-293 cells (ATCC) and derivatives were cultured in a 37 °C incubator with 5% CO2, in DMEM 
(Sigma, St Louis, MO, USA) supplemented with 10% FBS (Atlanta Biologicals, Norcross, GA, USA) 
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and 1% penicillin-streptomycin-Fungizone (Life Technologies). For arsenite treatment, cells were 
incubated with 50 mM sodium (meta)arsenite (NaAsO2, Sigma) for 1 h. For DDX6-FLAG-HA induction, 
cells were treated with 1 μg/mL doxycycline (Sigma) for 18 h. 
4.3. Immunoprecipitation 
For each sample, one 15 cm plate of cells at 80% confluency was rinsed with cold PBS, scraped 
into 2 mL NP-40 buffer (50 mM HEPES pH 7.5, 150 mM KCl, 2 mM EDTA, 1% NP40, one 
Complete mini protease inhibitor tablet and one PhosStop tablet per 10 mL (Roche, Basel, 
Switzerland)) and incubated on ice for 20 min. Protein lysates were then spun at 14,000 RPM for 10 min 
at 4 °C, and supernatant was used as the protein sample. The lysates were first incubated for 1 h at 4 °C 
with anti-FLAG agarose beads (Sigma) for the tandem immunoprecipitation, or with Protein G 
Dynabeads (Life Technologies) bound to an antibody recognizing GRAN2 (Sigma, HPA045542).  
The beads were washed 3 times in wash buffer (50 mM HEPES pH 7.5, 150 mM KCl, 2 mM EDTA, 
0.5% NP40). At this point, some samples were incubated for 10 min at room temperature with  
250 units benzonase (Sigma). For the tandem immunoprecipitation, protein complexes were eluted 
from the beads by 2 incubations with 3XFLAG peptide (Sigma, 100 μg/mL) for 5 min each. The 
resulting eluate was incubated with Protein G Dynabeads bound to an anti-HA antibody (Sigma, 
H3663) for 45 min at 4 °C. The bead-bound proteins were then washed 3 times with wash buffer, and 
either boiled in Laemmli buffer for Western blot (Biorad, Hercules, CA, USA), or washed 3 more 
times in 25 mM ammonium bicarbonate (ABC) for preparation for mass spectrometry analysis. 
4.4. Western Blot 
Lysates were prepared as for immunoprecipitation, using RIPA buffer (50 mM Tris pH 7.5, 1% NP40, 
0.1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, one Complete mini protease inhibitor tablet 
and 1 PhosStop tablet per 10 mL) in place of NP-40 buffer. Equal protein amounts were run on  
SDS-PAGE gels, transferred via wet electroblotting, and blocked in 5% milk in TBS-T (50 mM Tris  
pH 7.5, 150 mM NaCl, 0.1% Tween-20). The following primary antibodies were incubated with  
the blots overnight at a dilution of 1:1000 unless otherwise noted: anti-DDX6 (Abcam, Cambridge,  
United Kingdom, 4967), anti-FLAG (Sigma, F3165), anti-beta-actin (Cell Signaling, Beverly, MA, 
USA, 4967), anti-HA (Sigma, H6908), anti-NUFIP2 (Sigma, HPA017344, 1:250), anti-GRAN2 
(Sigma, HPA045542, 1:250), anti-GRAN1 (ProteinTech, Chicago, IL, USA, 20808-1-AP), anti-SUMO1 
(Abcam, ab32058). HRP-conjugated secondary antibodies were used at a dilution of 1:5000 for 1 h 
(GE Healthcare, Little Chalfont, UK). 
4.5. Blue Native Polyacrylamide Gel Electrophoresis 
A single anti-FLAG immunoprecipitation step was performed as described above, including elution 
with the 3X FLAG peptide. Eluates were separated using the NativePAGE system (Life Technologies) 
according to the manufacturer’s instructions, on a 1 mm 3%12% Bis-Tris gel. Gel bands from the 
entire lane were cut with a width of 2 mM from a GelCode Blue-stained gel (Pierce Biotechnology, 
Waltham, MA, USA), and processed for analysis by mass spectrometry as described below. 
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4.6. Sample Preparation for Mass Spectrometry 
For immunoprecipitation-derived samples, bead-bound proteins from immunoprecipitation experiments 
were digested and eluted by direct incubation with 50 ng trypsin in ABC overnight at 37 °C. The 
eluate was then reduced with dithiothreitol (DTT) and then alkylated with iodoacetamide (IAA). 
Formic acid and acetonitrile were added to final concentrations of 0.1% and 5% respectively. For gel 
slices, samples were destained in a buffer containing acetonitrile and ABC, reduced with DTT and then 
alkylated with IAA. The gel slices were dehydrated with acetonitrile, then resuspended with a trypsin 
digestion solution (100 ng trypsin per sample). Samples were digested overnight at 37 °C. All samples 
were cleaned with Aspire desalting tips (Thermo Fisher Scientific, New York, NY, USA) according to 
the manufacturer’s instructions as the final step before mass spectrometry analysis. 
4.7. Mass Spectrometry 
Mass spectrometry analysis was performed on an LTQ Orbitrap (Thermo Scientific) coupled to 
an Eksigent nano-LC Ultra HPLC (Absciex, Framingham, MA, USA). Samples were run on a 180 min 
(entire immunoprecipitation samples) or 30 min (gel slices) nonlinear gradient from 2% to 41% 
acetonitrile in 0.1% formic acid. Survey full-scan mass spectra were acquired from 300–2000 m/z, 
with a resolution of 60,000. The top 20 most intense ions from the survey scan were isolated and 
fragmented in the linear ion trap by collision-induced dissociation (normalized collision energy = 35 eV). 
The dynamic exclusion list (n = 500) used a retention time of 90 s and a repeat duration of 45 s 
(repeat count = 1), and preview scan mode was enabled. Ions of charge state = 1 or unassigned 
charge states were rejected. 
4.8. Immunofluorescence Imaging 
Cells were grown on fibronectin-coated coverslips (BD Biosciences), and fixed for 15 min in 4% 
paraformaldehyde followed by 10 min in cold methanol [90]. Primary antibodies were incubated for 1 h 
or overnight at the following concentrations: DDX6 (Santa Cruz Biotechnology, Dallas, TX, USA,  
sc-376433, 1:25), DCP1a (Abcam, ab47811), HA (Roche, 11867423001), NUFIP2 (Sigma, HPA017344, 
1:250), GRAN1 (ProteinTech, 20808-1-AP, 1:250), GRAN2 (Sigma, HPA045542, 1:500), PABPC1 
(Abcam, ab6125, 1:1000). Fluorescence-conjugated secondary antibodies were incubated for 1 h at a 
1:1000 dilution (Molecular Probes, Waltham, MA, USA). 
4.9. Bioinformatics and Data Analysis 
Evidence for previously established protein-protein interactions was taken from the BioGRID and 
INTACT databases [55,103], and searches of the literature. Functional enrichment of gene lists by GO 
annotation was performed using the ProfCom_GO statistical framework [104]. Western blots were 
quantified via the ImageJ program using standard densitometry techniques [105]. 
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4.10. Mass Spectrometry Data Analysis 
RAW files from the mass spectrometer were converted to the mzXML format with ReadW  
(version 4.3.1, which is available in the TransProteomic Pipeline (TPP) platform (http://tools. 
proteomecenter-.org/software.php)) and then searched against a human proteome database 
(ENSEMBL 67) with X!Tandem/the Global Proteome Machine Cyclone XE (version 2.2.1 Beavis 
Informatics Ltd., Winnipeg, Canada) [106]. Searches were conducted using the following parameters: 
fragment monoisotopic mass error 0.4 Da, parent monoisotopic mass error plus /+20 ppm, spectrum 
conditioning dynamic range 100 and total peaks 50, maximum parent charge 4, minimum parent M + H 
500.0, minimum fragment mz 150.0, minimum peaks 15, cleavage site [RK] [107], maximum missed 
cleavage sites = 1 with a refinement step for unanticipated cleavage, complete carbamidomethylation of 
cysteines (+57 Da), partial oxidation of methionine (+16 Da), and partial deamidation of asparagine and 
glutamine (1 Da) in the refinement step only. Protein abundance factor (PAF) was calculated as 
previously described [108], using an average of the three benzonase-treated replicates. The MS/MS data 
were also searched against a uniprot-based human protein sequence database including protein sequences 
of common contaminants by MaxQuant version 1.3.0.3. A FASTA file of the human reference proteome 
was obtained from UniProt (06-2012, 20,231 entries) [107]. For the searches, trypsin was defined as the 
protease. The search included carbamidomethyl of cysteine as a fixed modification and N-acetylation 
of protein and oxidation of methionine as variable modifications. Up to two missed cleavages were 
allowed for protease digestion and peptide had to be fully tryptic. The mass spectrometry proteomics 
data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository [109] 
with the data identifier PXD002070. 
4.11. Sumoylation Bioinformatics Analysis 
The software SUMOsp was used to identify sumoylation sites, with the “high-confidence” cutoff 
values [110]. Statistical significance of enrichment of both sumoylated proteins and sumoylation sites 
was calculated using hypergeometric distributions. 
5. Conclusions 
In sum, its multitude of interaction partners and memberships in protein complexes places DDX6 
into a key position with a central role in RNA localization and metabolism. While several of  
the interaction partners have been known before, no study has placed DDX6 into the center of its 
interaction network, screening for interaction partners both in a comprehensive and highly specific 
way, minimizing the false-positive rates that are normally high. We present the first study, generate 
new hypotheses on the protein SUMOylation in DDX6 function and its putative role in splicing, and 
describe new stress granule components. 
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